# A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants

> **NCT05701423** · — · TERMINATED · sponsor: **Biogen** · enrollment: 34 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Natalizumab

## Key facts

- **NCT ID:** NCT05701423
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** TERMINATED
- **Start date:** 2023-02-08
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-07-31
- **Target enrollment:** 34 (ACTUAL)
- **Why stopped:** Due to low enrolment the sponsor decided to terminate the study
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05701423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05701423, "A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05701423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*